Advertisement

CEN Case Reports

, Volume 4, Issue 2, pp 126–130 | Cite as

Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolate mofetil

  • Kaori Mochizuki
  • Ken Kayakabe
  • Keiju HiromuraEmail author
  • Masayasu Ando
  • Noriyuki Sakurai
  • Hidekazu Ikeuchi
  • Toru Sakairi
  • Yoriaki Kaneko
  • Akito Maeshima
  • Yoshihisa Nojima
Case Report

Abstract

Treatment of severe lupus nephritis (LN) has been controversial, and according to recent guidelines and recommendations, cyclophosphamide still remains a first-line therapy. Herein, we present the case of a 37-year-old female patient who developed rapidly progressive glomerulonephritis, which was histologically diagnosed as class IV + V LN, with a large number of cellular to fibrocellular crescents (62 % of glomeruli). Although the patient was considered to have the most severe form of LN, complete remission was achieved within 6 months by multi-target therapy using tacrolimus and mycophenolate mofetil combined with methylprednisolone pulse therapy. Our experience suggests that multi-target therapy could be a potential treatment option for patients with severe crescentic LN.

Keywords

Crescentic lupus nephritis Multi-target therapy Mycophenolate mofetil Lupus nephritis Tacrolimus 

Notes

Conflict of interest

K. Hiromura has received honoraria for lectures and research grants from Astellas Pharma Inc and honoraria for lectures from Chugai Pharmaceutical, Co., Ltd. H. Ikeuchi has received research grants from Chugai Pharmaceutical, Co., Ltd. A. Maeshima has received research grants from Astellas Pharma Inc. Y. Nojima has received honoraria for lectures and research grants from Astellas Pharma Inc and research grants from Chugai Pharmaceutical, Co., Ltd.

References

  1. 1.
    Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797–808.CrossRefGoogle Scholar
  2. 2.
    Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Kidney Disease. Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Chapter 12: Lupus nephritis. Kidney Int. 2012;2(Suppl):221–32.Google Scholar
  4. 4.
    Mok CC, Yap DY, Navarra SV, et al. Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis. 2013;16:625–36.CrossRefPubMedGoogle Scholar
  5. 5.
    Rovin BH, Parikh SV, Hebert LA, et al. Lupus nephritis: induction therapy in severe lupus nephritis–should MMF be considered the drug of choice? Clin J Am Soc Nephrol. 2013;8:147–53.CrossRefPubMedGoogle Scholar
  6. 6.
    Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V + IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001–10.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Ikeuchi H, Hiromura K, Takahashi T, et al. Efficacy and safety of multi-target therapy using a combination of. Mod Rheumatol. 2014;24:618–25.Google Scholar
  8. 8.
    Hogan J, Schwenk M, Radhakrishnan J. Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Kidney Int. 2012;82:1256–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Yu F, Tan Y, Liu G, et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 2009;76:307–17.CrossRefPubMedGoogle Scholar
  10. 10.
    Chen S, Tang Z, Zhang Y, et al. Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis. Am J Nephrol. 2013;38:445–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Boumpas DT, Austin HA 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Tang Z, Yang G, Yu C, et al. Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrol (Carlton). 2008;13:702–7.CrossRefGoogle Scholar
  13. 13.
    Liu LL, Jiang Y, Wang LN, et al. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs. 2012;72:1521–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Song AT, Abdala E, Bonazzi PR, et al. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?–A mini-review. Braz J Infect Dis. 2006;10:132–8.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2014

Authors and Affiliations

  • Kaori Mochizuki
    • 1
  • Ken Kayakabe
    • 1
  • Keiju Hiromura
    • 1
    Email author
  • Masayasu Ando
    • 1
  • Noriyuki Sakurai
    • 1
  • Hidekazu Ikeuchi
    • 1
  • Toru Sakairi
    • 1
  • Yoriaki Kaneko
    • 1
  • Akito Maeshima
    • 1
  • Yoshihisa Nojima
    • 1
  1. 1.Department of Medicine and Clinical ScienceGunma University Graduate School of MedicineMaebashiJapan

Personalised recommendations